<DOC>
	<DOCNO>NCT00776659</DOCNO>
	<brief_summary>To generate follow data patient early breast cancer treat Aromasin速 adjuvant set India . - Efficacy treatment Aromasin速 - Safety treatment Aromasin速</brief_summary>
	<brief_title>An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin</brief_title>
	<detailed_description>NA The study prematurely discontinue due slow enrollment keep mind observational nature study . The decision terminate take 16th June 2012 LSLV occur 14th September , 2012 . It note safety concern see study factor decision .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Patients early breast cancer receive adjuvant therapy Aromasin速 eligible . Patients present situ cancer , recurrent metastatic breast cancer , 2nd primary include . Patients know hypersensitivity Exemestane metabolite also include .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>An Observational Study Indian Breast Cancer Patients Receiving Adjuvant Therapy Aromasin</keyword>
	<keyword>Antineoplastic Hormonal Drugs</keyword>
	<keyword>Aromasin</keyword>
</DOC>